Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein
DE Cabin, K Shimazu, D Murphy, NB Cole… - Journal of …, 2002 - Soc Neuroscience
Although the mutation of α-synuclein, a protein associated with presynaptic vesicles, is
implicated in the etiology and pathogenesis of Parkinson's disease, the biological function of the …
implicated in the etiology and pathogenesis of Parkinson's disease, the biological function of the …
Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background
DE Cabin, S Gispert-Sanchez, D Murphy… - Neurobiology of …, 2005 - Elsevier
α-Synuclein is a major component of Lewy bodies, neuronal inclusions diagnostic for Parkinson’s
disease (PD). While an Ala53Thr mutation in α-synuclein can cause PD in humans, in …
disease (PD). While an Ala53Thr mutation in α-synuclein can cause PD in humans, in …
[HTML][HTML] Parkinson's disease: overview of transcription factor regulation, genetics, and cellular and animal models
N Xia, DE Cabin, F Fang, RA Reijo Pera - Frontiers in Neuroscience, 2022 - frontiersin.org
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, affecting
nearly 7–10 million people worldwide. Over the last decade, there has been considerable …
nearly 7–10 million people worldwide. Over the last decade, there has been considerable …
Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints
…, JB Carroll, HB Kordasiewicz, DE Cabin… - Nucleic acids …, 2020 - academic.oup.com
Lowering of prion protein (PrP) expression in the brain is a genetically validated therapeutic
hypothesis in prion disease. We recently showed that antisense oligonucleotide (ASO)-…
hypothesis in prion disease. We recently showed that antisense oligonucleotide (ASO)-…
[HTML][HTML] Antisense oligonucleotides extend survival of prion-infected mice
…, A Kraus, SL Schreiber, C Mazur, DE Cabin… - JCI insight, 2019 - ncbi.nlm.nih.gov
Prion disease is a fatal, incurable neurodegenerative disease of humans and other mammals
caused by conversion of cellular prion protein (PrP C) into a self-propagating neurotoxic …
caused by conversion of cellular prion protein (PrP C) into a self-propagating neurotoxic …
Human and mouse α-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element
…, A Dehejia, O Chiba-Falek, DE Cabin… - Genome …, 2001 - genome.cshlp.org
The human α-synuclein gene (SNCA) encodes a presynaptic nerve terminal protein that was
originally identified as a precursor of the non-β-amyloid component of Alzheimer's disease …
originally identified as a precursor of the non-β-amyloid component of Alzheimer's disease …
[HTML][HTML] Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration
…, J Peterson, RW Price, DE Cabin… - The Journal of …, 2012 - Am Soc Clin Investig
Progress in neurodegenerative disease research is hampered by the lack of biomarkers of
neuronal dysfunction. We here identified a class of cerebrospinal fluid–based (CSF-based) …
neuronal dysfunction. We here identified a class of cerebrospinal fluid–based (CSF-based) …
Therapeutic trial of anle138b in mouse models of genetic prion disease
…, GA Carlson, EV Minikel, DE Cabin - Journal of …, 2023 - Am Soc Microbiol
Phenotypic screening has yielded small-molecule inhibitors of prion replication that are
effective in vivo against certain prion strains but not others. Here, we sought to test the small …
effective in vivo against certain prion strains but not others. Here, we sought to test the small …
[HTML][HTML] Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS
…, A McManus, MR Moore, J Liu, DE Cabin… - JCI insight, 2022 - ncbi.nlm.nih.gov
Prion protein (PrP) concentration controls the kinetics of prion replication and is a genetically
and pharmacologically validated therapeutic target for prion disease. In order to evaluate …
and pharmacologically validated therapeutic target for prion disease. In order to evaluate …
Molecular genetic characterization and comparative mapping of the humanPCP4 gene
DE Cabin, K Gardiner, RH Reeves - Somatic cell and molecular genetics, 1996 - Springer
The mousePcp4 gene is highly expressed in brain, primarily in cerebellar Purkinje cells. It
maps to chromosome 16 (Chr 16), in a region of conserved synteny with human chromosome …
maps to chromosome 16 (Chr 16), in a region of conserved synteny with human chromosome …
